[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495080":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":38,"responsibleParty":105,"collaborators":18,"id":108,"slug":109,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":110,"sex":116,"minAge":117,"maxAge":18,"enrollmentInfo":118,"targetDuration":18,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":41,"whyStopped":18,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"University of Manitoba","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Group","EXPERIMENTAL","Participants randomized to the intervention group will be provided with a wireless BP cuff, weight scale, transcutaneous O2 sat monitor, wearable motion tracker and mobile tablet with the VIEWER application. Patients will be trained to use the VIEWER platform either virtually or in person. Patients will be guided through a daily self-assessment routine via the app (BP, weight, O2 saturation, step count upload) and weekly ESAS-r survey. Participants will use the VIEWER platform for 12 months ( or until dialysis initiation) in addition to receiving usual care. Additionally, participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months (or every 3 months until dialysis initiation), and the System Usability Scale (SUS) at 12 months.",[13],"Device: VIEWER virtual care platform",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","NO_INTERVENTION","Participants randomized to the control group will continue to receive usual care either virtually via telephone or video call or in person depending on COVID-19 restrictions in place. Participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months (or every 3 months until dialysis initiation).",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DEVICE","VIEWER virtual care platform","VIEWER is a tablet based, CKD specific home telemonitoring platform developed by our team of patients and researchers that integrates data from a wireless blood pressure cuff, weigh scale, transcutaneous O2 sat monitor and wearable motion tracker via a tablet and custom app.",[9],[26],{"name":27,"affiliation":5,"role":28},"Claudio Rigatto, MD","PRINCIPAL_INVESTIGATOR",[30,34],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","204-631-3834","crigatto@sogh.mb.ca",{"name":35,"role":31,"phone":36,"phoneExt":18,"email":37},"Zahra Solati, PhD","204-632-3662","ZSOLATI@SOGH.MB.CA",[39,58,67,76,92],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"St. Boniface Hospital","RECRUITING","Winnipeg","Manitoba","R2H 2A6","Canada","CA",{"type":48,"coordinates":49},"Point",[50,51],-97.14704,49.8844,{"lat":51,"lon":50},[54],{"name":55,"role":31,"phone":56,"phoneExt":18,"email":57},"Reid Whitlock, MSc","(204) 631-3834","rwhitlock@sogh.mb.ca",{"facility":59,"status":41,"city":42,"state":43,"zip":60,"country":45,"countryCode":46,"cosmosGeoPoint":61,"geoPoint":63,"contacts":64},"Chronic Disease Innovation Centre, Seven Oaks Hospital","R2V 3M3",{"type":48,"coordinates":62},[50,51],{"lat":51,"lon":50},[65],{"name":66,"role":31,"phone":56,"phoneExt":18,"email":57},"Reid Whitlock",{"facility":68,"status":41,"city":42,"state":43,"zip":69,"country":45,"countryCode":46,"cosmosGeoPoint":70,"geoPoint":72,"contacts":73},"Health Sciences Centre","R3A 1R9",{"type":48,"coordinates":71},[50,51],{"lat":51,"lon":50},[74],{"name":55,"role":31,"phone":75,"phoneExt":18,"email":57},"2046313834",{"facility":77,"status":41,"city":78,"state":79,"zip":80,"country":45,"countryCode":46,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"London Health Sciences Centre","London","Ontario","N6A 5W9",{"type":48,"coordinates":82},[83,84],-81.23304,42.98339,{"lat":84,"lon":83},[87],{"name":88,"role":31,"phone":89,"phoneExt":90,"email":91},"Kathleen Koyle","519-685-8500","56214","Kathleen.Koyle@lhsc.on.ca",{"facility":93,"status":41,"city":94,"state":79,"zip":95,"country":45,"countryCode":46,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Scarborough Health Network - General Hospital","Scarborough Village","M1P 2V5",{"type":48,"coordinates":97},[98,99],-79.22124,43.73899,{"lat":99,"lon":98},[102],{"name":103,"role":31,"phone":18,"phoneExt":18,"email":104},"Harika Kuppala","hkuppala@shn.ca",{"type":28,"investigatorFullName":106,"investigatorTitle":107,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Claudio Rigatto","Principal Investigator","100495080","ckd-specific-telemonitoring-platform-to-minimize-adverse-outcomes-in-high-risk-ckd-patients-100495080",false,"NCT05726526","CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients","A Pragmatic Randomized Controlled Trial of a CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients","VIEWER","Inclusion Criteria:\n\n* \\>18 years of age\n* Patient or primary caregiver can read and speak English\n* Patient or patients substitute decision maker is able to provide informed consent\n* Patient or primary care giver cognitively and physically capable and willing to use the VIEWER mobile application and perform self-measurements (i.e. weight, BP, etc.)\n* Have stage 5 CKD (2 measurements of eGFR \\\u003C15ml\u002Fmin\u002F1.73m2); eGFR will be calculated with the CKD-EPI equation, or have \\>40% chance of beginning dialysis in the next 2 years based on the Kidney Failure Risk Equation\n* Followed in a multidisciplinary CKD clinic\n\nExclusion Criteria:\n\n* Inability of self or caregiver assisted self-monitoring using VIEWER","ALL","18 Years",{"count":119,"type":120},340,"ESTIMATED","INTERVENTIONAL",[123],"NA","The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and\u002For hospitalizations\u002For increase the perceived safety of virtual care among patients and providers.",[126,127],"Chronic Kidney Disease Stage 5","End Stage Renal Disease",[129,130,131,132],"telemonitoring","chronic kidney disease","suboptimal dialysis initiation","digital health","2026-03-05",{"date":135,"type":136},"2026-03-09","ACTUAL",{"date":138,"type":136},"2022-06-30",{"date":140,"type":120},"2028-03-30",{"name":5,"class":6},5]